This commentary discusses the findings of a randomized clinical trial of trastuzumab vs a biosimilar in patients with metastatic breast cancer that was published in JAMA and posits 3 questions for consideration moving forward in the development and clinical use of biosimilars.
http://ift.tt/2kqSrkQ
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Summary Insulinomas are rare neuroendocrine tumours that classically present with fasting hypoglycaemia. This case report discusses an un...
-
The online platform for Taylor & Francis Online content New for Canadian Journal of Remote Sen...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου